Drugs Monitor, Page 28

(05 Aug 2020) Favipiravir- demonstrated rapid antiviral response against SARS-CoV-2

August 6, 2020

AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial https://doi.org/10.1101/2020.07.26.20154724 In May 2020 the Russian Ministry of Health granted fast-track marketing authorization to RNA polymerase inhibitor AVIFAVIR (favipiravir) for the treatment… Continue reading "(05 Aug 2020) Favipiravir- demonstrated rapid antiviral response against SARS-CoV-2"

(04 August 2020) Interferons- Higher rate of recovery

August 6, 2020

Therapeutic effectiveness of interferon alpha 2b treatment for COVID-19 patient recovery https://doi.org/10.1101/2020.07.28.20157974.this A prospective observational study (RPCEC00000318) was implemented to monitor a therapeutic intervention with IFN alpha-2b used in the national protocol for COVID-19 attending in Cuba. Patients received therapy… Continue reading "(04 August 2020) Interferons- Higher rate of recovery"

(03 Aug 2020) Lopinavir/R & Chloroquine- did not improve the prognosis or shorten the clinical course of COVID-19

August 4, 2020

A retrospective evaluation on the efficacy of Lopinavir/ritonavir and chloroquine to treat non-severe COVID-19 patients https://doi.org/10.1097/QAI.0000000000002452 A retrospective study to summarize the clinical practices of non-severe patients with COVID-19 receiving the standard care, LPV/r or chloroquine was conducted. Of the… Continue reading "(03 Aug 2020) Lopinavir/R & Chloroquine- did not improve the prognosis or shorten the clinical course of COVID-19"

(02 Aug 2020) Tocilizumab- No impact on mortality in severe COVID-19 patients

August 4, 2020

Impact of tocilizumab administration on mortality in severe COVID-19 https://doi.org/10.1101/2020.07.30.20114959 A total of 132 patients were included in the matched dataset (tocilizumab=66; standard of care=66). Approximately 73% of the patients were male. Hypertension (55%), diabetes mellitus (31%), and chronic pulmonary… Continue reading "(02 Aug 2020) Tocilizumab- No impact on mortality in severe COVID-19 patients"

(01 Aug 2020) Lopinavir/Ritonavir- a high frequency of DDI between LPV-r for treating COVID-19

August 4, 2020

High rate of major drug-drug interactions of lopinavir-ritonavir for COVID-19 treatment https://doi.org/10.1101/2020.07.30.20165027 Overall, 469 patients were diagnosed of COVID-19, 125 (27%) of them were prescribed LPV-r. LPV-r had potential DDI with concomitant medications in 97 (78%, 95% CI: 69%-85%) patients,… Continue reading "(01 Aug 2020) Lopinavir/Ritonavir- a high frequency of DDI between LPV-r for treating COVID-19"

(30 July 2020) Itolizumab- associated with a reduction in the COVID-19 disease worsening and mortality

August 1, 2020

Use of a humanized anti-CD6 monoclonal antibody (itolizumab) in elderly patients with moderate COVID-19 https://doi.org/10.1101/2020.07.24.20153833 To preliminary assess the effect of itolizumab (CT-RPCEC00000311), a control group was selected among the Cuban COVID-19 patients, which did not receive immunomodulatory therapy. Control… Continue reading "(30 July 2020) Itolizumab- associated with a reduction in the COVID-19 disease worsening and mortality"

(30 July 2020) Tocilizumab- not associated with reduced 30-day all-cause mortality, but shorter duration on ventilatory support

August 1, 2020

The study aimed to observe the impact of the IL-6 receptor antagonist tocilizumab on the outcome of patients admitted to the intensive care unit (ICU) with acute respiratory distress syndrome (ARDS) related to COVID-19. Eighty-seven patients with confirmed SARS-CoV-2 infection… Continue reading "(30 July 2020) Tocilizumab- not associated with reduced 30-day all-cause mortality, but shorter duration on ventilatory support"

(30 July 2020) Tocilizumab- earlier use beneficial for survival, length of hospitalization, and duration of oxygen support

August 1, 2020

Appropriate use of Tocilizumab in COVID-19 Infection https://www.ijidonline.com/article/S1201-9712(20)30580-4/fulltext In total, 43 patients were included; 70% of the patients was male; the median age was 64 (min-max: 27-94), 6 (14%) patients were fatal. The median duration of oxygen support before the… Continue reading "(30 July 2020) Tocilizumab- earlier use beneficial for survival, length of hospitalization, and duration of oxygen support"

(29 July 2020) Tocilizumab- safe and is associated with reduced invasive mechanical ventilation requirement

July 30, 2020

Safety and efficacy of tocilizumab in the treatment of severe acute respiratory syndrome coronavirus-2 pneumonia: A retrospective cohort study http://www.ijmm.org/text.asp?2020/38/1/117/290693 This retrospective study was conducted at a tertiary care hospital from April 20 2020 to May 21 2020. The primary… Continue reading "(29 July 2020) Tocilizumab- safe and is associated with reduced invasive mechanical ventilation requirement"

(29 July 2020) Tinospora Cordifolia- could benefit treating asymptomatic Covid-19 patients

July 30, 2020

A Retrospective Study on Efficacy and Safety of Guduchi Ghan Vati for Covid-19 Asymptomatic Patients https://www.medrxiv.org/content/10.1101/2020.07.23.20160424v1 Objective of present study (NCT04480398) was to evaluate the clinical outcome in Covid-19 confirmed asymptomatic to mild symptomatic patients who had received Ayurveda and… Continue reading "(29 July 2020) Tinospora Cordifolia- could benefit treating asymptomatic Covid-19 patients"